Outcomes of HLA-haploidentical hematopoietic cell transplantation according to the disease status
| Outcomes . | Acute leukemia . | MDS (n = 15) . | ||
|---|---|---|---|---|
| CR1 (n = 15) . | CR2/CR3 (n = 19) . | REF (n = 34) . | ||
| Engraftment, ANCs > 500/μL | ||||
| Yes | 15 | 19 | 28 | 14 |
| Censored | — | — | 6 | 1 |
| Disease progression | — | — | 4 | 1 |
| TRM | — | — | 2 | — |
| Median days (range) | 12 (11-18) | 13 (11-18) | 14 (9-23) | 16 (11-53) |
| Engraftment, platelets > 20 000/μL | ||||
| Yes | 15 | 19 | 25 | 13 |
| Median days (range) | 15 (11-119) | 17 (11-27) | 22 (12-76) | 25 (13-105) |
| Acute GVHD | ||||
| All | 4 | 4 | 7 | 5 |
| Grades 2-4 | 3 | 3 | 6 | 4 |
| Grade 3 or 4 | 1 | 1 | 2 | 2 |
| Chronic GVHD | ||||
| All | 8 | 8 | 5 | 7 |
| Moderate to severe | 6 | 4 | 4 | 6 |
| Severe | 5 | 2 | 2 | 6 |
| Secondary graft failure | — | — | 2 | 2 |
| Positive CMV antigenemia | 11 | 17 | 22 | 8 |
| CMV diseases | 1 | 2 | 1 | — |
| Colitis | 1 | 2 | — | — |
| Esophagitis | — | — | 1 | — |
| EBV reactivation (/evaluated) | 9/14 | 8/11 | 9/15 | 4/9 |
| EBV-PTLD | 1 | — | 1 | 1 |
| Progression/recurrence of leukemia/MDS | 4 | 6 | 24 | 3 |
| TRM | 2 | 2 | 8 | 4 |
| Death | 6 | 9 | 30 | 7 |
| Causes of death | ||||
| Progression/recurrence of leukemia/MDS | 4 | 7 | 22 | 3 |
| Acute GVHD | — | 1 | 2 | 1 |
| Secondary graft failure | — | — | 1 | 2 |
| EBV-related PTLD | 1 | — | 1 | — |
| CMV colitis | — | 1 | — | — |
| Idiopathic interstitial pneumonitis | — | — | 1 | — |
| Pulmonary hemorrhage | — | — | — | 1 |
| H1N1 influenza pneumonia | 1 | — | — | — |
| Acute meningoencephalitis | — | — | 1 | — |
| Pneumonia | — | — | 1 | — |
| Sepsis | — | — | 1 | — |
| Outcomes . | Acute leukemia . | MDS (n = 15) . | ||
|---|---|---|---|---|
| CR1 (n = 15) . | CR2/CR3 (n = 19) . | REF (n = 34) . | ||
| Engraftment, ANCs > 500/μL | ||||
| Yes | 15 | 19 | 28 | 14 |
| Censored | — | — | 6 | 1 |
| Disease progression | — | — | 4 | 1 |
| TRM | — | — | 2 | — |
| Median days (range) | 12 (11-18) | 13 (11-18) | 14 (9-23) | 16 (11-53) |
| Engraftment, platelets > 20 000/μL | ||||
| Yes | 15 | 19 | 25 | 13 |
| Median days (range) | 15 (11-119) | 17 (11-27) | 22 (12-76) | 25 (13-105) |
| Acute GVHD | ||||
| All | 4 | 4 | 7 | 5 |
| Grades 2-4 | 3 | 3 | 6 | 4 |
| Grade 3 or 4 | 1 | 1 | 2 | 2 |
| Chronic GVHD | ||||
| All | 8 | 8 | 5 | 7 |
| Moderate to severe | 6 | 4 | 4 | 6 |
| Severe | 5 | 2 | 2 | 6 |
| Secondary graft failure | — | — | 2 | 2 |
| Positive CMV antigenemia | 11 | 17 | 22 | 8 |
| CMV diseases | 1 | 2 | 1 | — |
| Colitis | 1 | 2 | — | — |
| Esophagitis | — | — | 1 | — |
| EBV reactivation (/evaluated) | 9/14 | 8/11 | 9/15 | 4/9 |
| EBV-PTLD | 1 | — | 1 | 1 |
| Progression/recurrence of leukemia/MDS | 4 | 6 | 24 | 3 |
| TRM | 2 | 2 | 8 | 4 |
| Death | 6 | 9 | 30 | 7 |
| Causes of death | ||||
| Progression/recurrence of leukemia/MDS | 4 | 7 | 22 | 3 |
| Acute GVHD | — | 1 | 2 | 1 |
| Secondary graft failure | — | — | 1 | 2 |
| EBV-related PTLD | 1 | — | 1 | — |
| CMV colitis | — | 1 | — | — |
| Idiopathic interstitial pneumonitis | — | — | 1 | — |
| Pulmonary hemorrhage | — | — | — | 1 |
| H1N1 influenza pneumonia | 1 | — | — | — |
| Acute meningoencephalitis | — | — | 1 | — |
| Pneumonia | — | — | 1 | — |
| Sepsis | — | — | 1 | — |
REF indicates refractory disease; —, not applicable; and PTLD, posttransplantation lymphoproliferative disorder.